Andrew Jergens lawsuit
This article was originally published in The Rose Sheet
Executive SummaryU.S. Court of Appeals for the Federal Circuit affirms November 2002 Washington state district court decision denying attorney fees and dismissing antitrust counterclaim against Q-Pharma in patent infringement case. Q-Pharma filed suit against Jergens in 2001, claiming firm's Curel Age Defying Therapeutic Moisturizing Lotion with Coenzyme Q10 infringed '373 patent covering use of "therapeutically effective amount of" ingredient CoQ10 in admixture. Jergens counterclaimed for judgments of noninfringement, invalidity and unenforceability of the patent. Q-Pharma withdrew its suit after discovering Curel lotion contained only 0.00005% CoQ10 by weight, and the court subsequently dismissed all claims related to the suit except Jergens' antitrust counterclaim...
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.